Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

Daniela E. Matei; Kenneth P. Nephew

doi:10.1016/j.ygyno.2009.09.043

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

Daniela E. Matei^*, Kenneth P. Nephew

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

79 Scopus citations

Abstract

Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.

Original language	English (US)
Pages (from-to)	195-201
Number of pages	7
Journal	Gynecologic oncology
Volume	116
Issue number	2
DOIs	https://doi.org/10.1016/j.ygyno.2009.09.043
State	Published - Feb 2010

Keywords

Chemosensitization
DNMTI
Epigenetics
HDAC inhibitor
Ovarian cancer
Platinum resistance

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2009.09.043

Cite this

@article{645c8922ec5643829eb10115716c2e97,

title = "Epigenetic therapies for chemoresensitization of epithelial ovarian cancer",

abstract = "Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.",

keywords = "Chemosensitization, DNMTI, Epigenetics, HDAC inhibitor, Ovarian cancer, Platinum resistance",

author = "Matei, {Daniela E.} and Nephew, {Kenneth P.}",

note = "Funding Information: This work was funded by the National Cancer Institute Awards CA133877-01 (to DM), CA085289 and CA113001 (to KPN), and awards from the Phi Beta Psi Sorority (Brownsburg, IN) (to KPN).",

year = "2010",

month = feb,

doi = "10.1016/j.ygyno.2009.09.043",

language = "English (US)",

volume = "116",

pages = "195--201",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

AU - Matei, Daniela E.

AU - Nephew, Kenneth P.

N1 - Funding Information: This work was funded by the National Cancer Institute Awards CA133877-01 (to DM), CA085289 and CA113001 (to KPN), and awards from the Phi Beta Psi Sorority (Brownsburg, IN) (to KPN).

PY - 2010/2

Y1 - 2010/2

N2 - Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.

AB - Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.

KW - Chemosensitization

KW - DNMTI

KW - Epigenetics

KW - HDAC inhibitor

KW - Ovarian cancer

KW - Platinum resistance

UR - http://www.scopus.com/inward/record.url?scp=73949106115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949106115&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.09.043

DO - 10.1016/j.ygyno.2009.09.043

M3 - Review article

C2 - 19854495

AN - SCOPUS:73949106115

SN - 0090-8258

VL - 116

SP - 195

EP - 201

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 2

ER -

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this